NCT00587119View on ClinicalTrials.gov

Oral Budesonide in the Treatment of Patients With Primary Biliary Cirrhosis and Overlap Features of Autoimmune Hepatitis

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2007

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
Primary Biliary CirrhosisAutoimmune Hepatitis
Interventions
DRUG

Budesonide

Oral Budesonide, 3 mg three times daily, will be given for 1 year.

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER